Department of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, 1425 Madison Avenue, 11th Floor Room 70-E, New York, NY 10029, USA.
Division of Liver Diseases, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, 1425 Madison Avenue, 11th Floor Room 70-E, New York, NY 10029, USA.
Surg Pathol Clin. 2022 Sep;15(3):529-539. doi: 10.1016/j.path.2022.05.006. Epub 2022 Aug 2.
Cholangiocarcinoma (CCA) is a group of malignancies of the bile ducts with high mortality rates and limited treatment options. In the past decades, remarkable efforts have been dedicated toward elucidating the specific molecular signaling pathways and oncogenic loops driving cholangiocarcinogenesis to ultimately develop more effective therapies. Despite some recent advances, an extensive intra- and inter-tumor heterogeneity together with a poorly understood immunosuppressive microenvironment significantly compromises the efficacy of available treatments. Here, we provide a concise review of the latest advances and current knowledge of the molecular pathogenesis of CCA focusing on clinically relevant aberrations as well as future research avenues.
胆管癌(CCA)是一组具有高死亡率和有限治疗选择的胆管恶性肿瘤。在过去的几十年中,人们做出了巨大的努力来阐明驱动胆管癌发生的特定分子信号通路和致癌环,以最终开发更有效的治疗方法。尽管最近取得了一些进展,但广泛的肿瘤内和肿瘤间异质性以及对免疫抑制微环境的了解不足,显著影响了现有治疗方法的疗效。在这里,我们提供了对 CCA 分子发病机制的最新进展和现有知识的简要回顾,重点关注临床相关的异常以及未来的研究途径。